Abstract Body

Background

Life expectancy of people with HIV on antiretroviral therapy (ART) has increased dramatically over the last 30 years. Our objective was to determine the aggregate clinical benefit of ART in the US.

Methods

Using a microsimulation model of HIV disease, we projected lifetime survival benefits for people initiating ART since 1996. We simulated ART regimens for cohorts newly diagnosed with HIV and compared projected life-years between those treated (ART) and untreated (No ART). We defined 7 ART eras, denoting improvements in initial and salvage ART regimens over time (Table). People surviving to later eras switch to the best available regimen upon diagnosis with virologic failure. Model inputs include annual numbers of new HIV diagnoses (1996=89,963 to 2023=38,850), CD4 at diagnosis (Era 1=269 cells/uL to Era 7=371 cells/uL), 30-day HIV care linkage (Era 1=46% to Era 7=82%), 2-year engagement in HIV care (Era1=49% to Era7=87%), and 1-year virologic suppression on initial ART (Era 1=47% to Era 7=82%). We report life-years gained from ART per person and for the US population, projected over a lifetime and as will be realized through 2025. We varied key parameters in sensitivity analysis.

Results

Since 1996, 1.5 million people have been newly diagnosed with HIV, leading to a projected lifetime survival benefit of 23.1 million life-years. Of these, 7.0 million years will have been realized by year-end 2025, with 16.1 million more years expected to be accrued over the lifetime in people with HIV diagnosed through 2025 (Table). ART in Eras 1 and 2 with PIs and NNRTIs increased life expectancy by 9.5-10.6 years/person compared with No ART. In Eras 3, 4, and 5, with boosted PIs, improved boosted PIs, and better salvage regimens, life expectancy increased by 12.1-15.8 years. Uptake of 1st and 2nd generation INSTIs increased life expectancy by 17.5-19.9 years. In sensitivity analyses, varying rates of linkage to care, engagement in care, and virologic suppression on initial ART regimen yielded projected benefits of 22.1-25.7 million life-years saved. For most eras, ensuring timely linkage to ART for everyone would have conferred higher survival benefit than introducing new regimens in subsequent eras.

Conclusions

Life expectancy benefits from ART in the US have improved markedly since its introduction in 1996. Over 23 million years of life are projected to be saved in people with HIV in the US due to ART use over the past 30 years.

Table or Figure